Sanofi announced plans to invest €1.3 billion ($1.4 billion) in a new insulin production facility at its BioCampus in Frankfurt Höchst, Germany, where it produces the insulin brand Lantus. The new plant, slated for completion by 2029, aims to secure long-term insulin supply for people with diabetes worldwide while bolstering European supply chain resilience.According to a company release, the project will see the construction of a 36,000-square-meter facility that makes use of "state-of-the-art digital and network solutions to ensure affordable and accessible insulin care." The plant will replace Sanofi's existing insulin production systems at the site."With this project, we are reaffirming our commitment to diabetes patients worldwide and leveraging the many years of expertise at our Frankfurt BioCampus with its highly qualified employees," said Brendan O'Callaghan, Sanofi's global head of manufacturing and supply. "Our commitment to promoting European health sovereignty remains distinctive and unique."The new facility is expected to create "several hundred" highly skilled jobs, the company said. The BioCampus already plays an important role in Sanofi's operations, covering the entire insulin production chain from the production of active ingredients to the assembly of pens and auto-injectors, as well as global distribution.The BioCampus employs over 4000 people in the insulin value chain and supplies 20 different insulin products to patients in around 80 countries.